Parameter_Type	Parameters
Common_Inputs	Cell type (human airway epithelial cells, primary cells); patient characteristics (age, disease diagnosis and severity); 3D culture model type (MucilAir, EpiAirway, organotypic cultures); days at differentiation/ALI; disease diagnosis (asthma, COPD); medication use; oxidant type and concentration; exposure duration; ROS probe specifics (DCFDA, DHE, MitoSOX) and loading conditions; detection method (flow cytometry, microscopy, plate reader); study population; cohort description; disease definitions; exacerbation criteria; PM2.5 source and characterization; sample type (airway cells, tissues); differentiation status; acrolein concentration range
Common_Exposure	Oxidants (H₂O₂, cigarette smoke extract, PM2.5, acrolein, ozone, diesel exhaust particles); environmental exposures (air pollution, smoking, wildfire smoke); antioxidant treatments (type and dose); pathway inhibitors/activators (NRF2, NF-κB, MAPK); Western blot antibodies; ELISA platforms; immunofluorescence for nuclear translocation; reporter constructs; ChIP antibodies; qRT-PCR for target genes; exhaled breath condensate (EBC) collection; serum and BALF sampling; biomarker collection protocols; exposure assessment methods; multi-omics platforms (RNA-seq, MS proteomics, MS metabolomics/lipidomics)
Common_Outputs	ROS levels (fluorescence intensity, fold change); Lipid peroxidation products (MDA, 4-HNE, 8-isoprostane); Protein oxidation markers (protein carbonyls, nitrotyrosine); DNA damage (8-OHdG); Antioxidant capacity (GSH/GSSG ratio, SOD, catalase, GPx activities); Mitophagy marker expression (LC3, PINK1, Parkin); Inflammatory cytokine secretion (IL-6, IL-8); EGFR and MAPK activation (pEGFR, pERK); NRF2 activation (nuclear localization, ARE activity, target gene expression); NF-κB activation; MAPK phosphorylation (pERK, pJNK, pp38); Pathway-specific gene expression; Dose-response and time-course; EBC biomarker levels (8-isoprostane, MDA, H₂O₂); Serum and BALF oxidative markers; Correlation with FEV1 and disease severity; Association with exacerbation risk; Environmental exposure-biomarker relationships; Tissue viability; Barrier integrity (TEER); Cytotoxicity metrics (LDH, MTT, viability); Histological changes; Transcriptomic signatures; Proteomic changes (total and oxidized proteins); Metabolomic profiles (GSH metabolism, energy metabolism); Lipid peroxidation products; Integrated pathway analysis; Predictive biomarker signatures; Oxidative stress biomarker profiles; Inflammatory marker profiles; Phenotype/endotype classifications; Cluster characteristics; Molecular signatures; Clinical correlates of oxidative-inflammatory phenotypes
